Navitoclax Archives - Medical Conferences

Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis

Presented By

Prof. Naveen Pemmaraju, MD Anderson Cancer Center, TX, USA

Trial

Phase 3, TRANSFORM-1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:28

TRANSFORM-1: High spleen volume reduction rates for navitoclax plus ruxolitinib in myelofibrosis

Presented By

Prof. Naveen Pemmaraju, MD Anderson Cancer Center, TX, USA

Trial

Phase 3, TRANSFORM-1

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

Novel, orally available inhibitor of BCL-XL/BCL-2

Presented By

Dr Naveen Pemmaraju, MD Anderson Cancer Center, Texas, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:59

Venetoclax + navitoclax promising for R/R ALL or LL

Presented By

Prof. Elias Jabbour , University of Texas MS Anderson Cancer Centre, USA

Trial

Phase 1

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 12:23

site created by:

© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy

HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com